Status:
UNKNOWN
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
Lead Sponsor:
Ruijin Hospital
Conditions:
Spinal Metastases
Non-Small-Cell Lung Cancer Metastatic
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this study is to learn whether our own made predictive algorithm can be used as a clinical practical decision support for patients with NSCLC spinal metastasis. The scoring system consi...
Detailed Description
Investigators have performed a retrospective study on 176 patients with NSCLC spinal metastasis under the oversight of hospital's ethics committee, and investigators found that the use of EGFR-TKI, KP...
Eligibility Criteria
Inclusion
- Diagnosis by biopsy: Non-small-cell lung cancer, including non-squamous carcinoma and squamous cell carcinoma.
- Diagnosis through both nucleotide bone scan and MRI or PET-CT: spinal metastasis.
- Age 18-75 years.
- Have been or is about to be treated according to NCCN panel recommendation.
Exclusion
- Diagnosis by biopsy: other tumors.
- Irregular follow-up and lost follow-up
- Withdraw from the study for any reason
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2022
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT03363685
Start Date
November 1 2017
End Date
November 1 2022
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025